Global Health Ltd (MEDANTA) — shareholding pattern, promoter holding, financials and share price
About Global Health Ltd (MEDANTA)
Global Health Ltd operates in the Hospital industry, within the Healthcare sector. It trades on the NSE as MEDANTA and on the BSE under scrip code 543654. Its ISIN is INE474Q01031.
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. [1]
Global Health Limited (Medanta) is a leading healthcare provider in India, operating multi-specialty tertiary care hospitals across key regions with specialties in cardiology, oncology, neurology, and more.
The company has expanded its operations significantly over the years, with recent additions including a new facility in Noida and substantial growth in its Lucknow and Patna hospitals.
Listed peers in Hospital: Aster DM Healthcare Ltd, Narayana Hrudayalaya Ltd, Krishna Institute of Medical Sciences Ltd, Dr Agarwals Health Care Ltd, Rainbow Childrens Medicare Ltd, Park Medi World Ltd.
Valuation & Returns
10 Jul 2026At ₹1,335.6 a share on 10 Jul 2026, Global Health Ltd (MEDANTA) was valued at a price-to-earnings ratio of 64.81x against an industry P/E of 61.73x and a price-to-book of 10.6x on a book value of ₹125.95 per share as of Mar 2025. Solomo computes return on equity of 16.36% and return on capital employed of 19.35% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 64.81x
- Industry P/E
- 61.73x
- P/B
- 10.6x
- EPS (TTM)
- ₹20.61
- Book value / share
- ₹125.95
- ROE
- 16.36%
- ROCE
- 19.35%
- ROA
- 11.62%
- Debt / equity
- 0.21x
- Dividend yield
- 0.04%
- EBITDA margin
- 23.05%
- 52-week range
- ₹955.2 – ₹1,455.85
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Global Health Ltd (MEDANTA) reported revenue of ₹4,410 crore, net profit of ₹554 crore and earnings per share of ₹20.7. That compares with revenue of ₹3,692 crore and net profit of ₹481 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,159 crore and net profit ₹142 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 |
| Net profit (₹ cr) | 196 | 326 | 478 | 481 | 554 |
| EPS (₹) | 7.75 | 12.16 | 17.81 | 17.92 | 20.7 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 16.83% | 21.99% | 12.74% |
| Profit growth | 35.04% | 28.25% | 0.68% |
| Stock price CAGR | - | 24% | 0% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 33% of Global Health Ltd (MEDANTA) (down 0.01 pp QoQ), foreign institutional investors (FII) hold 9.46% and domestic institutional investors (DII) hold 16.89%. Market capitalisation was ₹35,911 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2022.
Largest disclosed public shareholders in Jun 2026: DUNEARN INVESTMENTS (MAURITIUS) PTE LTD 14.84%, SUNIL SACHDEVA 10.04%, RJ CORP LIMITED 6.58%, INVESCO INDIA ELSS TAX SAVER FUND 5.3%, KOTAK CONTRA FUND 3.53%, GOVERNMENT PENSION FUND GLOBAL 3.17%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 33% | - | 9.46% | 16.89% | 66.91% |
| Mar 2026 | 33.01% | - | 10.15% | 14.76% | 66.92% |
| Dec 2025 | 33.01% | - | 10.53% | 14% | 66.93% |
| Sep 2025 | 33.01% | - | 11.4% | 12.98% | 66.93% |
| Jun 2025 | 33.01% | - | 11.54% | 12.2% | 66.93% |
| Mar 2025 | 33.03% | - | 11.76% | 11.93% | 66.97% |
| Dec 2024 | 33.03% | - | 12.47% | 10.51% | 66.97% |
| Sep 2024 | 33.04% | - | 12.2% | 11.11% | 66.96% |